ALLTogether1- A Treatment study protocol of the ALLTogether Consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL) - ALLTogether1

Karolinska University Hospital0 个研究点目标入组 565 人开始时间: 待定最近更新: 2024年4月15日

试验速览

阶段: 3 期
状态: 招募中
发起方
入组人数: 565

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 0 至 64（—）

入选标准

•1. Patients newly diagnosed with T-lymphoblastic (T-cell) or B-lymphoblastic
•precursor (BCP) leukaemia (ALL) according to the WHO-classification of Tumours
•of Haematopetic and Lymphoid Tissues (Revised 4th edition 2017) and with a
•diagnosis confirmed by an accredited laboratory at a participating paediatric
•oncology or adult haematology centre.
•2. Age > 0 days and < 46 years (one day before 46th birthday) at the time of
•3. Patients with surface IG negative BCP-ALL and an IG::MYC rearrangement
•unless they have a concurrent BCL2/6 rearrangement. T-ALL patients with MYC
•translocations.
•4. Informed consent signed by the patient and/or parents/legal guardians
•according to country-specific age-related guidelines.
•5. The ALL diagnosis should be confirmed by an accredited laboratory at a
•participating paediatric oncology or adult haematology centre.
•6. The patient should be diagnosed and treated at a participating paediatric
•oncology or adult haematology centre in the participating countries.
•7. The patient should be a resident in one of the participating countries on a
•permanent basis or should intend to settle in a participating country, for
•instance by an application for asylum. Patients who are visiting the country as
•tourists should not be included. However, returning expatriots with primary
•diagnosis abroad may be included if no treatment has been administered and the
•diagnostic procedures are repeated at a participating centre.
•8. All women of childbearing potential (WOCBP) have to have a negative
•pregnancy test within 2 weeks prior to the start of treatment.
•For each intervention/randomisation an additional set of inclusion-criteria is

排除标准

•1. Age < 365 days at diagnosis and KMT2A-rearranged (KMT2A-r) BCP ALL
•(documented presence of a KMT2A-split by FISH and/or a KMT2A transcript). These
•patients will be transfered to an appropriate trial for KMT2A-r BCP infant ALL
•if available.
•2. Age > 45 years at diagnosis (from the 46th birthday onwards).
•3. Patients with a previous malignant diagnosis (ALL as a second malignant
•neoplasm - SMN).
•4. Relapse of ALL.
•5. Patients with mature B-ALL (as defined by Surface Ig positivity or
•documented presence of one of the t(8;14)(q24;q32), t(2;8)(p12;q24),
•t(8;22)(q24;q11) translocations involving the MYC gene and breakpoint as in
•mature B-NHL/ALL) or any patients with IG::MYC and a concurrent BCL2/6
•rearrangement.
•6. Patients with Ph-positive ALL (documented presence of t(9;22)(q34;q11)
•and/or of the BCR::ABL1 fusion transcript). These patients will be transferred
•to an adequate trial for t(9;22) if available.
•7. Previously known ALL prone syndromes (e.g. Li-Fraumeni syndrome, germline
•ETV6 mutation), except for Down syndrome. Exploration for such ALL prone
•syndromes is not mandatory and patients in whom genetic work-up reveals a new
•germline mutation (index-cases) will remain in the study.
•8. Treatment with systemic corticosteroids (>10mg/m2/day) for more than one
•week and/or other chemotherapeutic agents in a 4-week interval prior to
•diagnosis (pre-treatment).
•9. Pre-existing contraindications to any treatment according to the ALLTogether
•protocol (constitutional or acquired disease prior to the diagnosis of ALL
•preventing adequate treatment).
•10. Any other disease or condition, as determined by the investigator, which
•could interfere with the participation in the study according to the study
•protocol, or with the ability of the patients to cooperate and comply with the
•study procedures.
•11. Women of childbearing potential who are pregnant at the time of diagnosis.
•12. Women of childbearing potential and fertile men who are sexually active and
•are unwilling to use adequate contraception during therapy. Efficient birth
•control is required, see section 17.7.
•13. Female patients, who are breast-feeding.
•14. Essential data missing from the registration of characteristics at
•diagnosis (in consultation with the protocol chair).
•For each intervention/randomisation an additional set of exclusion-criteria is

研究者

发起方

Karolinska University Hospital

相似试验

进行中（未招募）

1 期

A study protocol for children and young adults 0-45 years of age with newly diagnosed acute lymphoblastic leukaemia (ALL)Acute lymphoblastic leukaemia (ALL)MedDRA version: 21.0Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-001795-38-LTKarolinska University Hospital6,430

招募中

3 期

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

2022-501050-11-01Karolinska University Hospital5,704

进行中（未招募）

1 期

EUCTR2018-001795-38-FIKarolinska University Hospital6,430

进行中（未招募）

1 期

A study protocol for children and young adults 0-45 years of age with newly diagnosed acute lymphoblastic leukaemia (ALL)

EUCTR2018-001795-38-DEKarolinska University Hospital6,430

招募中

1 期

A study protocol for children and young adults 1-45 years of age with newly diagnosed acute lymphoblastic leukaemia (ALL)Acute lymphoblastic leukaemia (ALL)MedDRA version: 21.0Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-001795-38-ISKarolinska University Hospital6,430